Clene Inc. Makes Strides in Developing CNM-Au8 to Address Neurodegenerative Conditions
Clene Inc. presents new findings and information about its lead drug candidate, CNM-Au8, at the recent Emerging Growth Conference 73, showcasing progress in addressing neurodegenerative conditions.
This news matters because it highlights the progress of a clinical-stage biopharmaceutical company in developing a drug candidate to treat neurodegenerative diseases, offering hope to patients and potential investment opportunities.
